Screener
Arrowhead Research ARWR EPS (Diluted)
EPS (Diluted) at other companies
Other financials
Where this comes from
Reported directly by Arrowhead Research in its filing.
Tagged under the XBRL concept us-gaap:EarningsPerShareDiluted.
The source filing: Arrowhead Research’s 10-Q, filed May 7, 2026.
- Filed
- May 7, 2026, 4:05 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0000879407-26-000047
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 | Six Months Ended March 31, 2026 | Six Months Ended March 31, 2025 |
|---|---|---|---|---|
| Net (loss) income attributable to Arrowhead Pharmaceuticals, Inc. | $(132,732) | $370,445 | $(101,919) | $197,360 |
| Net (loss) income per share attributable to Arrowhead Pharmaceuticals, Inc.: | ||||
| Basic | $(0.93) | $2.78 | $(0.73) | $1.53 |
| Diluted | $(0.93) | $2.75 | $(0.73) | $1.52 |
| Weighted-average shares used in calculating | ||||
| Basic | 142,417 | 133,363 | 139,762 | 129,059 |
| Diluted | 142,417 | 134,484 | 139,762 | 130,265 |
| Comprehensive (loss) income: |
ITEM 1. FINANCIAL STATEMENTS
FAQ
- What is Arrowhead Research's EPS (diluted)?
- Arrowhead Research (ARWR) reported EPS (diluted) of -$0.93 in Q1 2026.
- How has Arrowhead Research's EPS (diluted) changed year-over-year?
- Arrowhead Research's EPS (diluted) decreased by 133.8% year-over-year, from $2.75 to -$0.93.
- What is the long-term trend for Arrowhead Research's EPS (diluted)?
- Over 4 years (2021 to 2025), Arrowhead Research's EPS (diluted) has grown at a -50.8% compound annual growth rate (CAGR), from -$1.36 to -$0.08.
- What does EPS (diluted) mean?
- Net income divided by the weighted-average number of shares outstanding plus all potentially dilutive securities (stock options, convertibles, warrants). The most conservative EPS measure.
Ask your AI about Arrowhead Research's eps (diluted).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude